Neurodegenerative disease biomarker and drug discovery Protocols

Bioprotocols > Neurodegenerative disease biomarker and drug discovery

The protocols listed in this section are extracted from scientific journals or patents or laboratory websites. We have cited only the journals that are freely available to view. Please be informed that the free services offered by listed journals may not be available globally. If you find difficulty in viewing the journals listed in our site, please let us know.

140 items found, displaying 1 to 30.[First/Prev] 1, 2, 3, 4, 5 [Next/Last]

Assay for screening effectiveness of the active compounds in suppressing nicotine binding to specific receptor sites : Isolation of rat brain membrane and competitive binding assay using [3H]-nicotine

Assay for screening muscarinic receptor M1 positive allosteric modulators : Muscarinic FLIPR assay

Assays and methods for identification and characterization of molecular diagnostic biomarker for the diagnosis of Alzheimer's disease : [Cytokine protein expression (using bead arrays) and gene expression (using RT-PCR) analysis in mononuclear cells from spleen, blood and brain isolated from 3xTg-AD mouse model for human Alzheimer's disease] [Analysis cytokine production in peripheral tissues of 3XTg-AD mice using antibodies] [Gene expression analysis in 3XTg-AD brain and spleen tissue] [Identification of the candidate biomarker and testing in blood from patients with Alzheimer's disease and healthy controls using RT-PCR]

Assays and methods for the identification of splice variants (e.g. syndecan-2 splice variants) as a molecular diagnositc biomarkers of Alzheimer's disease : Identification and characterization of Syndecan-2 Splice Variants Using Comprehensive Bioinformatic Analyses and Electronic hybridization, Detection of Splice Variants in Alzheimer's Disease Brains Using RT-PCR, DNA Sequence Analysis of splice Variants and Comparison of Relative Levels of Splice Variant RNA in Brain, Cloning and Expression and Purification of Recombinant Splice Variant Protein and Generation of Polyclonal Antibodies, Analysis of the Effect of Splice Variants in Secretions of Beta Cleavage Products of APP in HEK293E Cell Cultures Using Western Blotting, Immunolocalization of the Splice Variant to the Neurofibrillary Tangles of Alzheimer's Disease

Assays and methods for screening the efficacy of electromagnetic field (EMF) exposure in reversing very advanced brain Abeta aggregation/deposition in mouse models : EMF treatment, Behavioral Testing, Open field activity to measure exploratory behavior and general activity, Balance beam to measure balance and general motor function, Y-maze spontaneous alternation to measure general activity and basic mnemonic function, Circular platform to measure spatial/reference learning and memory, RAWA task of spatial working memory, Visual Cliff to evaluate vision/depth perception, Body/brain temperature determinations, rCBF determinations in cerebral cortex, Abeta immunohistochemistry and image analysis, Determination of Abeta140 and 142 levels in plasma samples using ELISA, Statistical analysis

Assays and methods for evaluating the efficacy of immunization against beta-amyloid (Abeta) for the treatment of Alzheimers disease (juvenile non-human primate (NHP) model) : Analysis of antibody response to vaccinations by detecting anti-Abeta42 antibodies, Histopathologic evaluation and [11C]PiB positron emission tomography imaging of Abeta content in the brain, Analyses of amyloid load and oligomer species using ELISA and western blot, Assessment of microglial activation using [11C]PK11195 positron emission tomography imaging, Microglial quantification by immunohistochemistry and real-time PCR, Analysis of immune activation marker YKL40 release in the cerebrospinal fluid (CSF), Multiplex analysis of chemokines in CSF

Assays and methods for identifying serum biomarkers for the diagnosis of Alzheimer's disease (AD) : Isolation of plasma proteins and isobaric protein tagging and LC/MS/MS analysis, Characterization of biomarkers by Western blotting , Validation of selected biomarkers using Selective Reaction Monitoring (SRM)

Assays and methods for screening modulators of nicotinic acetylcholine receptors (nAChRs) for treating Alzheimer's disease and neuropsychiatric diseases : CNS nAChRs: Alpha 4 Beta 2 NNR Subtype Radioligand Binding Assays Using Membranes from Rat Cortex and SH-EP1/human alpha 4 beta 2 clonal cells, CNS nAChRs: Alpha 7 NNR Subtype Inhbition Binding Assay With [3H]MLA Using Rat Hippocampal Proteins, Drug Selectivity Assay for Human Ganglionic nAChR Subtype and Human Muscle nAChR Subtype, Memory Test Using a Three-Trial Object Recognition Test, Working Memory Assessment Using a Radial Arm Maze (RAM) Task, CYP Inhibition Studies (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4), In Vitro Secondary Pharmacology: Multiple Receptor Screening Assay, hERG Inhibition Assay

Assays and methods for screening compounds that are modulators of gamma secretase for treating Alzheimer's disease : Secretase Reaction and A beta Analysis in Whole Cells, MS Analysis of A beta Profile, CSF A beta Analysis, Matrix-assisted laser desorption/ionization mass spectrometric (MALDI MS) analysis of A beta

Assays and methods for screening N-methyl-D-aspartic acid (NMDA) receptor potentiators for treating neurodegenerative diseases, neuropsychiatric diseases and neurological diseases : NMDA Receptor Activity Assay Using Recombinant NMDA Receptors, Activity at Native NMDA Receptor Responses in Neurons from Basal Ganglia Slices, Potentiation of Homomeric GluR1 AMPA Receptors, Evaluation Human Ether-a-Go-Go Potassium Channel (hERG) Binding, Metabolic Stability Studies Using Pooled Human or Rat Liver Microsomes, High Throughput Bioassay to Identify Selective Modulators of NR2C- or NR2D-containing receptors

Assays and methods of screening compounds that decrease the activity of tetrahydrobiopterin (BH4) by increasing the expression of GTPCH-binding or activity of GTP cyclohydrolase feedback regulatory protein (GFRP) for treating neuropathic pain : Tissue and RNA Preparation from DRG, Microarray Analysis Using Affymetrix Rat Genome U34A Oligonucleotide Microarrays, Isotopic in Situ Hybridization of DRGs, GTP Cyclohydrolase I (GTPCH) Activity Assays by Measuring Biopterin or Neopterin Levels Using Fluorometric, radiolabel, Immunoassay, Spectrophotometry, and HPLC Techniques

Assays and methods for screening the efficacy of anti-glial fibrillary acidic protein (GFAP) antibodies for treating neurodegenerative diseases : Production of Anti-GFAP-Variable Domains of Camelid Heavy-Chain Antibodies (VHH Domains) Using Ribosome Display, Immunocytochemistry Analysis of GFAP on Mouse and Human Brain Sections Using Anti-GFAP-VHHS, Diffusion Analysis of VHH and mAb, Analysis of Alzheimer Disease Samples, Stereotaxic and Intranasal or Intravenous Administration of VHH in Mouse, In Vitro and In Vivo Analysis of the Capacity of Antibodies to Cross the Blood Brain Barrier (BBB) and Labels Specifically GFAP

Assays and methods for analyzing the genetic and functional association of SNPs with Alzheimer's and Parkinson's diseases : Isolation of DNA samples from peripheral blood of patients with late-onset Alzheimer's disease (LOAD) and Parkinson's diseases, Gene expression analysis using brain RNA, SNP genotyping Taqman technology and HumanHap300-Duo Genotyping BeadChips, Disease-risk association analysis by multivariate logistic regression analysis using an allelic dosage model, Age-at-diagnosis association analysis, Linkage disequilibrium analysis in HaploView with the solid spine algorithm, Pathway analysis using MetaCore

Assays and methods for evaluating ATP synthase beta subunit as a potenital therapeutic drug target for treating Parkinson's disease (using Drosophila park1 mutants) : Screening in vivo glutathionylated protein targets of Drosophila glutathione S-transferase Omega 1 (DmGSTO1A) by immnunoprecipitation with an anti-GSH antibody in adult thorax extracts, Protein identification by MALDI-TOF mass spectrometric analysis, In vitro glutathionylation assay using immunoproeciptated ATP synthase beta subunit and GSTO1, Effect of RNAi mediated downregulation of ATP synthase beta subunit on the induction of parkin mutant phenotypes (e.g. muscle degeneration and accumulation of tubulin), Effect of DmGSTO1A on ATP synthase activity by analyzing the assembly level of the F1F0-ATP synthase complex (Complex V) by blue native PAGE and Western blot analysis with an anti-ATP synthase alpha subunit antibody

Assays and methods for the production of recombinant antibodies that recognize A beta peptide or variants for the diagnosis of Alzheimer's disease : Maleoylation of the Carrier Protein and Coupling of the Maleoylated BTG with the Peptide, Immunization and Selection of Stable Antibody Producing Hybridoma Cells, Characterization of Antibodies Using ELISA and PepSpot TM Analysis and DotBlot Analysis and SDS PAGE Analysis and BIACORE Analysis, Sequencing Antibody Variable Regions, PCR-Amplification of Heavy and Light Chain Variable Regions and Cloning of PCR Products in pJET1.2, Cross Reactivity Analysis Using ELISA and Surface-Plasmon-Resonance (SPR), Optimization and Validation of Antibodies for a) ELISA for Brain Analysis and b) Immunohistochemistry

Assays for screening the application of mesenchymal stem cells (MSCs) secreting brain-derived neurotrophic factor (BDNF) for treating neurodegenerative diseases : [Isolation and Proliferation of Human MSCs] [ Induction of Human MSC into BDNF-Secreting Stem Cells] [ Assaying In-Vitro Neuroprotection of Neuroblastoma Cell Line SH-SY5Y Cells Against 6-OHDA Toxicity] [ Measurements of GDNF and BDNF Secretion Using ELISA] [ In Vivo Studies Using 6-OHDA Induced Striatal Lesion Rat Model (Stem Cell Transplantation-Behavioral Tests, MRI, Immunohistochemistry, Stereological Study, Dopamine Measurements by HPLC and Statistical Analysis)]

Assays for screening modulators of metabotropic glutamate R4 (mGluR4) receptor : [Metabotropic glutamate R4 (mGluR4) binding assay using membranes prepared from CHO cells expressing the human mGluR4 receptor] [ Fluorescent plate imaging reader (FLIPR) assay for mGluR4 potentiators]

Assays for screening rho kinase 2 (ROCK) inhibitors for treating Alzheimer's disease : [Rho kinase 2 (ROCK) activity inhibition assay using recombinant active rho kinase 2] [ Competition binding assay for analyzing kinase specificity] [ Effect of test compounds on neurite outgrowth in vitro] [ Assessment of memory function in an in vitro Long-term potentiation (LTP) model] [ In vivo memory assessment in rat models of Radial arm maze, Radial arm maze and Morris Water maze (MWM)]

Assays for characterizing antibodies that bind to von Willebrand Factor A (VWF-A) domain of a calcium channel subunit alpha 2 delta for treating Alzheimer's disease : [Generation and characterization monoclonal antibodies against VWF-A domain of calcium channel alpha 2 delta 1 and alpha 2 delta 2 subunit] [Tests in Alzheimer's disease mode- Contextual Fear Conditioning Test, Morris Water Maze Test, Analysis of soluble and insoluble A beta and of A beta plaque, Immunohistochemistry of A beta plaque density,Amyloid Beta Immunohistochemistry,Soluble and Insoluble Amyloid Beta 1-42 ELISA and Statistical Analysis]

Assays for characterizing antibodies that bind to von Willebrand Factor A (VWF-A) domain of a calcium channel subunit alpha 2 delta for treating amyotrophic lateral sclerosis (ALS) : [Generation and characterization monoclonal antibodies against VWF-A domain of calcium channel alpha 2 delta 1 and alpha 2 delta 2 subunit] [Tests in amyotrophic lateral sclerosis (ALS) models-Postural reflex test, Balance beam test, Screen test, Tail suspension test and Immunohistochemistry]

Assays for screening the efficacy of combination therapy containing a cocktail of antioxidants and vitamins for treating Alzheimer's disease : Cognitive Evaluation in Tg2576 Mice-(Spatial memory tests, Cortex-dependent contextual task and Novel object recognition), Physiological Evaluation in Tg2576 Mice-(Analysis of aggregation state of A beta), Therapeutic Evaluation in 3xTg-AD Mice- (Hippocampal dependent spatial memory analysis)

Assays for screening the efficacy of combination therapy for Parkinson's disease : In Vitro Neuroprotection Assay, In Vitro Rapid Screening of Drug Combinations Protecting from Cell Death, In Vivo Characterization of Drug Combinations in Models of Parkinson's Disease- (Effect on locomotion activity, Effect on brain dopamine levels)

Assays for screening compounds that activate Nrf2-ARE pathway for the treating neurodegenerative diseases : Spectrum library screen validation Using ARE reporter assay, Determination of EC50 using ARE reporter assay, Oxidative stress assay to determine whether preconditioning with NRF2-ARE inducing drugs could protect against a subsequent oxidative stress insult (serum withdrawal), MTT cell viability assay, Basal oxidative stress assay in G93A SOD1expressing NSC34 Cells (ALS cellular model), Total glutathione assay, Mutiplex PCR to detect changes in expression levels of target genes in the 1321N1 astrocyte cell line following treatment

Assays for screening compounds that modulate fatty acid amide hydrolase (FAAH) for treating Parkinson's disease : Compound IC50 Determination Using Fluorimetric Assay with Isolated hFAAH Microsomes, Compound IC50 Determination Using Radioactive Assay with hFAAH Microsomes, Fluorescent Assay Utilizing Substrate decanoyl 7-amino-4-methyl coumarin (D-AMC), Locomotor Activity Measurements in Reserpinized Rats, Turning in 6-Hydroxydopamine (6-OHDA)-Lesioned Rats, MPTP-Lesioned Monkeys

Assays for screening the efficacy of herbal medicines (e.g. hydroxychavicol from Piper betel leaves) for treating Alzheimer's disease : Acute Oral Safety Study in Balb/C Mice, Intracerebroventricular Injection of Compounds, Evaluation of Memory Retention Deficit by Single Trial Passive Avoidance Test, Effect of Compounds on beta-Secretase and gamma-Secretase Activities, Quantification of IL-1 beta , TNF-alpha, IL-6 and NO in Supernatant from Tissue Homogenate, Measurement of Lipid Peroxidation, Estimation of Reduced Glutathione, Acetylcholinesterase(AChE) Activity Assay, Blood Glucose Estimation, Evaluation of Cell-Surface Markers and Estimation of Intracellular Cytokines Using Flow Cytometry, Activity Assays Using Crude Betel Leaf Extract, Eugenol and Isoeugenol

Assays for screening melatonin receptor (MT1 and MT2) agonists : Determination of the Agonist Activity of compounds on MT1 or MT2 Receptors Using Recombinant Stable Cell Line Expressing Human MT1 OR MT2 Receptors and Co-expresses Mitochondrial Apoaequorin and the G alpha 16 subunit

Assays for screening compounds that bind to neurotrophin receptor p75 neurotrophin receptor (p75NTR or low affinity nerve growth factor receptor or LNGFR) for treating Alzheimer's disease : Computational modeling to generate a pharmacophore emulating a loop structure likely to interact with a receptor, Identification of compounds with potent neurotrophic activity using high-throughput virtual screening based on neurotrophin loop 1 models Testing the ability of compounds to prevent the degeneration of hippocampal neurons by analyzing brain-derived neurotrophic factor (BDNF) activity, p75 NTR antibody competition assay using NIH3T3 fibroblasts expressing either null vector or p75NTR, Analysis of the effect of compounds in hippocampal neuron survival using embryonic hippocampal neurons in culture, Analyzing the effects of compounds on induction of cell death of mature oligodendrocytes, Analyzing the effects of compounds on inhibition pro-NGF-Induced death, analyzing the effect of compounds on blocking A beta-induced neural degeneration

Assays for identifying inhibitors of voltage-dependent anion channel 1 (VDAC1) mRNA can be used for treating Parkinson's disease : Identification VDAC1 as a Mitochondrial Substrate of Parkin Using Immunoprecipitation Analysis and Parkin siRNA, Analysis of the Effect of VDAC1 Protein Regulators on the Neurons Transfected with Parkin shRNA, Effect of PINK1 Knockdown Using siRNA on VDAC1 Expression, Effect of VDAC1 Protein Regulators on the Mitochondrial Defects of Parkin Null Mouse mDA Neurons, Effect of VDAC1 Protein Regulators on the Synaptic Activity of Parkin Null Mouse mDA Neurons

Assays for screening adenosine A2A receptor antagonists for treating Parkinson's disease : Assay for measuring in vitro binding of compounds to human adenosine A2A receptors by determining the displacement of the adenosine A2A receptor selective radioligand [3H]-CGS 21680, Evaluation of potential anti-parkinsonian activity in vivo using haloperidol-induced hypolocomotion model and 6-OHDA Model

Assays for screening inhibitors of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for treating motor dysfunction caused neurodegenerative diseases : Analysis the effect of compounds on age-induced neuronal cell death using primary culture cerebellar granule cells (CGC), Analysis the effect of compounds on GAPDH mRNA and protein expression using Northern blotting and Western blotting, In vivo studies in rat models of motor dysfunction in spinal cord injury

140 items found, displaying 1 to 30.[First/Prev] 1, 2, 3, 4, 5 [Next/Last]